Automera

UPPTHERA

The company develops targeted protein degradation therapies for patients with cancer and rare diseases and provides platform technologies to pharmaceutical and biotechnology companies.

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

Biotheryx

The company develops protein degrader medicines for patients with cancer and inflammatory diseases.

Samsara Therapeutics

This company develops autophagy-activating small molecule therapeutics to treat neurodegenerative and age-related diseases for patients with conditions such as ALS and Parkinson’s.

Kymera Therapeutics

This biotechnology company develops small molecule medicines that degrade disease-causing proteins for patients with cancer and immune-inflammatory diseases.

ProtOS

This company develops artificial intelligence models to design de-novo proteins for the degradation of undruggable targets for the pharmaceutical and medical biotechnology industries.

Sibylla Biotech

This company develops small molecule protein degraders for pharmaceutical partners and clinical research to treat oncological and neurodegenerative diseases.

AbilityPharma

This company develops autophagy-inducing oral therapies for patients with various forms of cancer, including pancreatic, endometrial and lung cancer.